Alqahtan Saleh A, Brown Robert S
Liver Transplant Center, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland.
Gastroenterol Hepatol (N Y). 2023 Jan;19(1):20-29.
Obesity has become a global epidemic, adding to the burden of chronic diseases and disabilities. Metabolic syndrome, especially obesity, is a significant risk factor for nonalcoholic fatty liver disease, which is the most common indication for liver transplant (LT). The prevalence of obesity among the LT population is growing. Obesity increases the necessity of LT by playing a role in the development of nonalcoholic fatty liver disease, decompensated cirrhosis, and hepatocellular carcinoma, and it can also coexist with other diseases requiring LT. Therefore, LT teams must identify key aspects required to manage this high-risk population, but there are currently no defined recommendations for managing obesity in LT candidates. Although body mass index is often used to assess the weight of patients and classify them as overweight or obese, this measure may be inaccurate to use in patients with decompensated cirrhosis, as fluid overload or ascites can significantly add to the weight of patients. Diet and exercise remain the cornerstone of obesity management. Supervised weight loss before LT, without worsening frailty and sarcopenia, may be beneficial in reducing surgical risks and improving long-term LT outcomes. Bariatric surgery is another effective treatment for obesity, with sleeve gastrectomy currently conferring the best outcomes in LT recipients. However, evidence supporting the timing of bariatric surgery is lacking. Long-term patient and graft survival data in individuals with obesity following LT are scarce. Class 3 obesity (body mass index ≥40) further complicates the treatment of this patient population. This article discusses the impact of obesity on the outcome of LT.
肥胖已成为全球性流行病,加重了慢性病和残疾的负担。代谢综合征,尤其是肥胖,是非酒精性脂肪性肝病的重要危险因素,而非酒精性脂肪性肝病是肝移植(LT)最常见的适应证。肝移植人群中肥胖的患病率正在上升。肥胖通过在非酒精性脂肪性肝病、失代偿期肝硬化和肝细胞癌的发生发展中起作用,增加了肝移植的必要性,并且它还可能与其他需要肝移植的疾病共存。因此,肝移植团队必须确定管理这一高危人群所需的关键方面,但目前尚无针对肝移植候选者肥胖管理的明确建议。尽管体重指数常被用于评估患者体重并将其分类为超重或肥胖,但在失代偿期肝硬化患者中使用该指标可能不准确,因为液体超负荷或腹水会显著增加患者体重。饮食和运动仍然是肥胖管理的基石。在肝移植前进行有监督的体重减轻,同时不加重虚弱和肌肉减少症,可能有助于降低手术风险并改善肝移植的长期效果。减重手术是治疗肥胖的另一种有效方法,目前袖状胃切除术在肝移植受者中效果最佳。然而,支持减重手术时机的证据不足。肝移植后肥胖个体的长期患者和移植物存活数据稀缺。3级肥胖(体重指数≥40)使这一患者群体的治疗更加复杂。本文讨论了肥胖对肝移植结局的影响。